menu
    • menu
    [{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lazertinib","moa":"||Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||IL-10 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Applied Molecular Transport \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Applied Molecular Transport \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||Integrin beta-7","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||Integrin beta-7","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"SHL Medical AG","sponsor":"MoonLake Immunotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Collaboration","leadProduct":"Adalimumab","moa":"||Interleukin-17F | Interleukin 17A","graph1":"Immunology","graph2":"Phase II","graph3":"SHL Medical AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SHL Medical AG \/ MoonLake Immunotherapeutics","highestDevelopmentStatusID":"8","companyTruncated":"SHL Medical AG \/ MoonLake Immunotherapeutics"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||Interleukin-17F | Interleukin 17A","graph1":"Dermatology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Public Offering","leadProduct":"Adalimumab","moa":"||Interleukin-17F | Interleukin 17A","graph1":"Dermatology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0.40000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.40000000000000002,"dosageForm":"Injection","sponsorNew":"MoonLake Immunotherapeutics \/ SVB Securities","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ SVB Securities"},{"orgOrder":0,"company":"University of North Carolina","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Undisclosed","graph3":"University of North Carolina","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"University of North Carolina \/ AbbVie Inc","highestDevelopmentStatusID":"1","companyTruncated":"University of North Carolina \/ AbbVie Inc"},{"orgOrder":0,"company":"Transgene","sponsor":"BioInvent | Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transgene \/ BioInvent | Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ BioInvent | Merck & Co"},{"orgOrder":0,"company":"Transgene","sponsor":"BioInvent","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||TNF-alpha receptor||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transgene \/ BioInvent","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ BioInvent"},{"orgOrder":0,"company":"Transgene","sponsor":"BioInvent","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||TNF-alpha receptor||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transgene \/ BioInvent","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ BioInvent"},{"orgOrder":0,"company":"Transgene","sponsor":"BioInvent","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||TNF-alpha receptor||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transgene \/ BioInvent","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ BioInvent"},{"orgOrder":0,"company":"BioInvent","sponsor":"Transgene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||TNF-alpha receptor||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioInvent \/ Transgene","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Transgene"},{"orgOrder":0,"company":"BioInvent","sponsor":"Transgene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||TNF-alpha receptor||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioInvent \/ Transgene","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Transgene"},{"orgOrder":0,"company":"Transgene","sponsor":"BioInvent","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||TNF-alpha receptor||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transgene \/ BioInvent","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ BioInvent"},{"orgOrder":0,"company":"Transgene","sponsor":"BioInvent","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||TNF-alpha receptor||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transgene \/ BioInvent","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ BioInvent"},{"orgOrder":0,"company":"Transgene","sponsor":"BioInvent","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2022","type":"Collaboration","leadProduct":"Adalimumab","moa":"||TNF-alpha receptor||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transgene \/ BioInvent","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ BioInvent"},{"orgOrder":0,"company":"BioInvent","sponsor":"Transgene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||TNF-alpha receptor||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioInvent \/ Transgene","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Transgene"},{"orgOrder":0,"company":"Transgene","sponsor":"BioInvent","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||TNF-alpha receptor||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transgene \/ BioInvent","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ BioInvent"},{"orgOrder":0,"company":"Transgene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||TNF-alpha receptor||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transgene \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ Undisclosed"},{"orgOrder":0,"company":"Transgene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||TNF-alpha receptor||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transgene \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ Undisclosed"},{"orgOrder":0,"company":"BioInvent","sponsor":"Transgene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||TNF-alpha receptor||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioInvent \/ Transgene","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Transgene"},{"orgOrder":0,"company":"Institute for Developing Science and Health Initiatives, Bangladesh","sponsor":"Universal Medical College Hospital | Green Life Center for Rheumatic Care & Research, Bangladesh | Incepta Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BANGLADESH","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Institute for Developing Science and Health Initiatives, Bangladesh","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Institute for Developing Science and Health Initiatives, Bangladesh \/ Universal Medical College Hospital | Green Life Center for Rheumatic Care & Research, Bangladesh | Incepta Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Institute for Developing Science and Health Initiatives, Bangladesh \/ Universal Medical College Hospital | Green Life Center for Rheumatic Care & Research, Bangladesh | Incepta Pharmaceuticals"},{"orgOrder":0,"company":"Chinese SLE Treatment And Research Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Rare Diseases and Disorders","graph2":"Phase IV","graph3":"Chinese SLE Treatment And Research Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chinese SLE Treatment And Research Group \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Chinese SLE Treatment And Research Group \/ Undisclosed"},{"orgOrder":0,"company":"Hanyang University Seoul Hospital","sponsor":"Linical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Hanyang University Seoul Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hanyang University Seoul Hospital \/ Linical","highestDevelopmentStatusID":"11","companyTruncated":"Hanyang University Seoul Hospital \/ Linical"},{"orgOrder":0,"company":"Celltrion","sponsor":"Rani Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2023","type":"Partnership","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Preclinical","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Celltrion \/ Rani Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Celltrion \/ Rani Therapeutics"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio-Thera Solutions \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bio-Thera Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Organon","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Samsung Bioepis \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Organon"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Samsung Bioepis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"PPD","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ PPD","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ PPD"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Samsung Bioepis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Undisclosed"},{"orgOrder":0,"company":"Huons CO., LTD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Huons CO., LTD","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Huons CO., LTD \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Huons CO., LTD \/ Undisclosed"},{"orgOrder":0,"company":"Biocon Biologics","sponsor":"Viatris | IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase III","graph3":"Biocon Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biocon Biologics \/ Viatris | IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"Biocon Biologics \/ Viatris | IQVIA"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Samsung Bioepis \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Biogen"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Organon","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Samsung Bioepis \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Organon"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Organon","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Samsung Bioepis \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Organon"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Samsung Bioepis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Henlius Biotech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Henlius Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Biocon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biocon \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Biocon \/ Undisclosed"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Organon","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Samsung Bioepis \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Organon"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Organon","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Samsung Bioepis \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Organon"},{"orgOrder":0,"company":"Eisai","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eisai \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ AbbVie Inc"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Enzene Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Enzene Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enzene Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Enzene Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Cadila Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Cadila Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cadila Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Cadila Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"LG Life Sciences","sponsor":"Mochida Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"LG Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LG Life Sciences \/ Mochida Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"LG Life Sciences \/ Mochida Pharmaceutical"},{"orgOrder":0,"company":"LG Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Undisclosed","graph2":"Phase I","graph3":"LG Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LG Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"LG Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Undisclosed","graph2":"Phase I","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samsung Bioepis \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Samsung Bioepis \/ Undisclosed"},{"orgOrder":0,"company":"University of Erlangen-N\u00fcrnberg Medical School","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"University of Erlangen-N\u00fcrnberg Medical School","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Erlangen-N\u00fcrnberg Medical School \/ Abbott Laboratories","highestDevelopmentStatusID":"7","companyTruncated":"University of Erlangen-N\u00fcrnberg Medical School \/ Abbott Laboratories"},{"orgOrder":0,"company":"Regionshospitalet Silkeborg","sponsor":"Abbott Laboratories | Medtronic plc | Central Denmark Region","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Rheumatology","graph2":"Phase IV","graph3":"Regionshospitalet Silkeborg","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regionshospitalet Silkeborg \/ Abbott Laboratories | Medtronic plc | Central Denmark Region","highestDevelopmentStatusID":"11","companyTruncated":"Regionshospitalet Silkeborg \/ Abbott Laboratories | Medtronic plc | Central Denmark Region"},{"orgOrder":0,"company":"Odense University Hospital","sponsor":"University of Southern Denmark | Hvidovre University Hospital | Aarhus University Hospital | AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Odense University Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Odense University Hospital \/ University of Southern Denmark | Hvidovre University Hospital | Aarhus University Hospital | AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"Odense University Hospital \/ University of Southern Denmark | Hvidovre University Hospital | Aarhus University Hospital | AbbVie Inc"},{"orgOrder":0,"company":"The Rheumatological Center of Helsinki","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FINLAND","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"The Rheumatological Center of Helsinki","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Rheumatological Center of Helsinki \/ Abbott Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"The Rheumatological Center of Helsinki \/ Abbott Laboratories"},{"orgOrder":0,"company":"University of Helsinki","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FINLAND","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"University of Helsinki","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Helsinki \/ AbbVie Inc","highestDevelopmentStatusID":"11","companyTruncated":"University of Helsinki \/ AbbVie Inc"},{"orgOrder":0,"company":"Centre Hospitalier Universitaire de Saint Etienne","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Centre Hospitalier Universitaire de Saint Etienne","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Centre Hospitalier Universitaire de Saint Etienne \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Centre Hospitalier Universitaire de Saint Etienne \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives \/ Undisclosed"},{"orgOrder":0,"company":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives \/ AbbVie Inc","highestDevelopmentStatusID":"11","companyTruncated":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives \/ AbbVie Inc"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Abbott Laboratories","highestDevelopmentStatusID":"9","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Abbott Laboratories"},{"orgOrder":0,"company":"University Medical Center Groningen","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Gastroenterology","graph2":"Phase I","graph3":"University Medical Center Groningen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Medical Center Groningen \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"University Medical Center Groningen \/ AbbVie Inc"},{"orgOrder":0,"company":"Maastricht University Medical Center","sponsor":"Maastricht University | ZonMw","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Maastricht University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maastricht University Medical Center \/ Maastricht University | ZonMw","highestDevelopmentStatusID":"11","companyTruncated":"Maastricht University Medical Center \/ Maastricht University | ZonMw"},{"orgOrder":0,"company":"Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa","sponsor":"Abbott Laboratories | TFS Trial Form Support","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa \/ Abbott Laboratories | TFS Trial Form Support","highestDevelopmentStatusID":"10","companyTruncated":"Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa \/ Abbott Laboratories | TFS Trial Form Support"},{"orgOrder":0,"company":"Karolinska Institutet","sponsor":"Abbott Laboratories | Swedish Foundation for Strategic Research | The Swedish Research Council","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Undisclosed","graph3":"Karolinska Institutet","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Karolinska Institutet \/ Abbott Laboratories | Swedish Foundation for Strategic Research | The Swedish Research Council","highestDevelopmentStatusID":"1","companyTruncated":"Karolinska Institutet \/ Abbott Laboratories | Swedish Foundation for Strategic Research | The Swedish Research Council"},{"orgOrder":0,"company":"Skane University Hospital","sponsor":"Abbott Laboratories | The Swedish Research Council | The Swedish Rheumatism Ass | Crafoord Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Skane University Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Skane University Hospital \/ Abbott Laboratories | The Swedish Research Council | The Swedish Rheumatism Ass | Crafoord Foundation","highestDevelopmentStatusID":"11","companyTruncated":"Skane University Hospital \/ Abbott Laboratories | The Swedish Research Council | The Swedish Rheumatism Ass | Crafoord Foundation"},{"orgOrder":0,"company":"Care Arthritis","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Care Arthritis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Care Arthritis \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Care Arthritis \/ AbbVie Inc"},{"orgOrder":0,"company":"University of Leeds","sponsor":"AbbVie Inc | Theorem","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"University of Leeds","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Leeds \/ AbbVie Inc | Theorem","highestDevelopmentStatusID":"11","companyTruncated":"University of Leeds \/ AbbVie Inc | Theorem"},{"orgOrder":0,"company":"University of Leeds","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase II","graph3":"University of Leeds","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Leeds \/ Abbott Laboratories","highestDevelopmentStatusID":"8","companyTruncated":"University of Leeds \/ Abbott Laboratories"},{"orgOrder":0,"company":"Heinrich-Heine University, Duesseldorf","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Heinrich-Heine University, Duesseldorf","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Heinrich-Heine University, Duesseldorf \/ Abbott Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Heinrich-Heine University, Duesseldorf \/ Abbott Laboratories"},{"orgOrder":0,"company":"Transgene","sponsor":"BioInvent","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||TNF-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transgene \/ BioInvent","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ BioInvent"},{"orgOrder":0,"company":"BioInvent","sponsor":"Transgene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||TNF-alpha receptor||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioInvent \/ Transgene","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Transgene"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Hexal AG","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sandoz B2B \/ Hexal AG","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Hexal AG"},{"orgOrder":0,"company":"Alvotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Undisclosed"},{"orgOrder":0,"company":"Alvotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Undisclosed"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Hexal AG","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase III","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sandoz B2B \/ Hexal AG","highestDevelopmentStatusID":"10","companyTruncated":"Sandoz B2B \/ Hexal AG"},{"orgOrder":0,"company":"University of Oxford","sponsor":"National Institute for Health Research, UK | 180 Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Oxford \/ National Institute for Health Research, UK | 180 Life Sciences","highestDevelopmentStatusID":"9","companyTruncated":"University of Oxford \/ National Institute for Health Research, UK | 180 Life Sciences"},{"orgOrder":0,"company":"Alvotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Undisclosed"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sandoz B2B \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Undisclosed"},{"orgOrder":0,"company":"Alvotech","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ STADA Arzneimittel","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ STADA Arzneimittel"},{"orgOrder":0,"company":"Alvotech","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ STADA Arzneimittel","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ STADA Arzneimittel"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fresenius Kabi AG \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AG \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Arecor","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Arecor","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arecor \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arecor \/ Undisclosed"},{"orgOrder":0,"company":"Alvotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Undisclosed"},{"orgOrder":0,"company":"Alvotech","sponsor":"Bioventure Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Bioventure Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Bioventure Healthcare"},{"orgOrder":0,"company":"Alvotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Undisclosed"},{"orgOrder":0,"company":"Alvotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Undisclosed"},{"orgOrder":0,"company":"Alvotech","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Alvotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2024","type":"Agreement","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Undisclosed"},{"orgOrder":0,"company":"Alvotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Undisclosed"},{"orgOrder":0,"company":"Alvotech","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ STADA Arzneimittel","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ STADA Arzneimittel"},{"orgOrder":0,"company":"Alvotech","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2023","type":"Partnership","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Alvotech","sponsor":"Bioventure Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Bioventure Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Bioventure Healthcare"},{"orgOrder":0,"company":"Alvotech","sponsor":"Cipla","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Cipla","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Cipla"},{"orgOrder":0,"company":"Alvotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Undisclosed"},{"orgOrder":0,"company":"Alvotech","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ STADA Arzneimittel","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ STADA Arzneimittel"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sandoz B2B \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Undisclosed"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sandoz B2B \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Quallent Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2024","type":"Agreement","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Quallent Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Quallent Pharmaceuticals"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fresenius Kabi AB Brunna \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AB Brunna \/ Undisclosed"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Samsung Bioepis","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2020","type":"Partnership","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mundipharma \/ Samsung Bioepis","highestDevelopmentStatusID":"15","companyTruncated":"Mundipharma \/ Samsung Bioepis"},{"orgOrder":0,"company":"Alvotech","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ STADA Arzneimittel","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ STADA Arzneimittel"},{"orgOrder":0,"company":"Binnopharm Group","sponsor":"Mabwell","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Antibody, Unconjugated","year":"2022","type":"Licensing Agreement","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Binnopharm Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Binnopharm Group \/ Mabwell","highestDevelopmentStatusID":"15","companyTruncated":"Binnopharm Group \/ Mabwell"},{"orgOrder":0,"company":"Alvotech","sponsor":"Assia Chemical Industries Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Assia Chemical Industries Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Assia Chemical Industries Ltd"},{"orgOrder":0,"company":"Alvotech","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2021","type":"Private Placement","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.10000000000000001,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Alvotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Undisclosed"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sandoz B2B \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Undisclosed"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sandoz B2B \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Undisclosed"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sandoz B2B \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Undisclosed"},{"orgOrder":0,"company":"Alvotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alvotech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Undisclosed"},{"orgOrder":0,"company":"University of Oxford","sponsor":"Department of Health, UK | Wellcome Trust | 180 Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Oxford \/ Department of Health, UK | Wellcome Trust | 180 Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"University of Oxford \/ Department of Health, UK | Wellcome Trust | 180 Therapeutics"},{"orgOrder":0,"company":"Biocad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"RUSSIA","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Undisclosed","graph2":"Phase I","graph3":"Biocad","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocad \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biocad \/ Undisclosed"},{"orgOrder":0,"company":"Alvotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Undisclosed","graph2":"Phase I","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alvotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Alvotech \/ Undisclosed"},{"orgOrder":0,"company":"Alvotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Undisclosed","graph2":"Phase I","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alvotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Alvotech \/ Undisclosed"},{"orgOrder":0,"company":"medac","sponsor":"Fresenius Kabi AB Brunna","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2020","type":"Agreement","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"medac","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"medac \/ Fresenius Kabi","highestDevelopmentStatusID":"15","companyTruncated":"medac \/ Fresenius Kabi"},{"orgOrder":0,"company":"Alvotech","sponsor":"DKSH","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2020","type":"Partnership","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alvotech \/ DKSH","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ DKSH"},{"orgOrder":0,"company":"Tel Aviv Sourasky Medical Center (Ichilov Hospital)","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Tel Aviv Sourasky Medical Center (Ichilov Hospital)","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tel Aviv Sourasky Medical Center (Ichilov Hospital) \/ Abbott Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Tel Aviv Sourasky Medical Center (Ichilov Hospital) \/ Abbott Laboratories"},{"orgOrder":0,"company":"Rabin Medical Center","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Undisclosed","graph3":"Rabin Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rabin Medical Center \/ Abbott Laboratories","highestDevelopmentStatusID":"1","companyTruncated":"Rabin Medical Center \/ Abbott Laboratories"},{"orgOrder":0,"company":"Clalit","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Clalit","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clalit \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Clalit \/ Undisclosed"},{"orgOrder":0,"company":"CinnaGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRAN","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"CinnaGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CinnaGen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CinnaGen \/ Undisclosed"},{"orgOrder":0,"company":"CinnaGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"IRAN","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Undisclosed","graph2":"Phase I","graph3":"CinnaGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CinnaGen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CinnaGen \/ Undisclosed"},{"orgOrder":0,"company":"Rambam Health Care Campus","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Rambam Health Care Campus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rambam Health Care Campus \/ Abbott Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Rambam Health Care Campus \/ Abbott Laboratories"},{"orgOrder":0,"company":"ICStudy","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Urology","graph2":"Phase III","graph3":"ICStudy","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ICStudy \/ Abbott Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"ICStudy \/ Abbott Laboratories"},{"orgOrder":0,"company":"Universit\u00e9 de Sherbrooke","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Universit\u00e9 de Sherbrooke","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universit\u00e9 de Sherbrooke \/ AbbVie Inc","highestDevelopmentStatusID":"11","companyTruncated":"Universit\u00e9 de Sherbrooke \/ AbbVie Inc"},{"orgOrder":0,"company":"Wayne State University","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Wayne State University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wayne State University \/ Abbott Laboratories","highestDevelopmentStatusID":"7","companyTruncated":"Wayne State University \/ Abbott Laboratories"},{"orgOrder":0,"company":"Reade Rheumatology Research Institute","sponsor":"ZonMw | Sint Maartenskliniek","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Reade Rheumatology Research Institute","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Reade Rheumatology Research Institute \/ ZonMw | Sint Maartenskliniek","highestDevelopmentStatusID":"11","companyTruncated":"Reade Rheumatology Research Institute \/ ZonMw | Sint Maartenskliniek"},{"orgOrder":0,"company":"Reade Rheumatology Research Institute","sponsor":"ZonMw | Sint Maartenskliniek","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Reade Rheumatology Research Institute","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Reade Rheumatology Research Institute \/ ZonMw | Sint Maartenskliniek","highestDevelopmentStatusID":"11","companyTruncated":"Reade Rheumatology Research Institute \/ ZonMw | Sint Maartenskliniek"},{"orgOrder":0,"company":"Superior Biologics","sponsor":"Coherus Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Agreement","leadProduct":"Adalimumab","moa":"||TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Superior Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Superior Biologics \/ Coherus Biosciences","highestDevelopmentStatusID":"15","companyTruncated":"Superior Biologics \/ Coherus Biosciences"},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"University of Pennsylvania","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Pennsylvania \/ AbbVie Inc","highestDevelopmentStatusID":"11","companyTruncated":"University of Pennsylvania \/ AbbVie Inc"},{"orgOrder":0,"company":"Progenity","sponsor":"Crohn\u2019s & Colitis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Funding","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Preclinical","graph3":"Progenity","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Progenity \/ Crohn\u2019s & Colitis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Progenity \/ Crohn\u2019s & Colitis Foundation"},{"orgOrder":0,"company":"Progenity","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Preclinical","graph3":"Progenity","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Progenity \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Progenity \/ Undisclosed"},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Preclinical","graph3":"Rani Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rani Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Rani Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Preclinical","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biora Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Biora Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Preclinical","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biora Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Biora Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Progenity","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Preclinical","graph3":"Progenity","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Progenity \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Progenity \/ Undisclosed"},{"orgOrder":0,"company":"Progenity","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Preclinical","graph3":"Progenity","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Progenity \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Progenity \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Mount Sinai Hospital, Canada","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Mount Sinai Hospital, Canada","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Mount Sinai Hospital, Canada"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Laboratorio Echevarne | Pivotal S.L.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Laboratorio Echevarne | Pivotal S.L.","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Laboratorio Echevarne | Pivotal S.L."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"IST GmbH | Hannover Medical School | Improvement by Movement","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ IST GmbH | Hannover Medical School | Improvement by Movement","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ IST GmbH | Hannover Medical School | Improvement by Movement"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Abbott Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abbott Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Eisai"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Innovaderm","sponsor":"Abbott Laboratories | Montreal Heart Institute","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"Innovaderm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovaderm \/ Abbott Laboratories | Montreal Heart Institute","highestDevelopmentStatusID":"11","companyTruncated":"Innovaderm \/ Abbott Laboratories | Montreal Heart Institute"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Rheumatology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Abbott Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abbott Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Abbott Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abbott Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ GSK"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Undisclosed","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"180 Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"180 Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Public Offering","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"180 Life Sciences \/ Alliance Global Partners","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Alliance Global Partners"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Public Offering","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"180 Life Sciences \/ Alliance Global Partners","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Alliance Global Partners"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Public Offering","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"180 Life Sciences \/ Alliance Global Partners","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Alliance Global Partners"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"180 Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Coherus Biosciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Coherus Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Mark Cuban Cost Plus Drug Company","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Agreement","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Coherus Biosciences \/ Mark Cuban Cost Plus Drug Company","highestDevelopmentStatusID":"15","companyTruncated":"Coherus Biosciences \/ Mark Cuban Cost Plus Drug Company"},{"orgOrder":0,"company":"Organon","sponsor":"Samsung Bioepis","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Organon \/ Samsung Bioepis","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Samsung Bioepis"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Public Offering","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"180 Life Sciences \/ Alliance Global Partners","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Alliance Global Partners"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Public Offering","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"180 Life Sciences \/ Alliance Global Partners","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Alliance Global Partners"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"180 Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"180 Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Public Offering","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"180 Life Sciences \/ Alliance Global Partners","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Alliance Global Partners"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Public Offering","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"180 Life Sciences \/ Alliance Global Partners","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Alliance Global Partners"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"180 Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"180 Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"University of Oxford","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"180 Life Sciences \/ University of Oxford","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ University of Oxford"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"180 Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Eisai"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Eisai"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Eisai"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Hong Kong King-Friend Industrial Co. Ltd","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Divestment","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Coherus Biosciences","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"Coherus Biosciences \/ Hong Kong King-Friend Industrial Co. Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Coherus Biosciences \/ Hong Kong King-Friend Industrial Co. Ltd"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Coherus Biosciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Coherus Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase III","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Coherus Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Coherus Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Preclinical","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biora Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Biora Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Preclinical","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biora Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Biora Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"NIHR","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"180 Life Sciences \/ NIHR","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ NIHR"},{"orgOrder":0,"company":"Innovaderm","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"Innovaderm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovaderm \/ Abbott Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"Innovaderm \/ Abbott Laboratories"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Viatris","sponsor":"Viatris","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase III","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Viatris \/ Viatris","highestDevelopmentStatusID":"10","companyTruncated":"Viatris \/ Viatris"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Undisclosed","graph2":"Phase I","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Innovaderm","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"Innovaderm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovaderm \/ Abbott Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"Innovaderm \/ Abbott Laboratories"},{"orgOrder":0,"company":"Progenity","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Progenity","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Progenity \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Progenity \/ Undisclosed"},{"orgOrder":0,"company":"St Vincent's Hospital Melbourne","sponsor":"Australasian Gastro Intestinal Research Foundation | AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"St Vincent's Hospital Melbourne","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"St Vincent's Hospital Melbourne \/ Australasian Gastro Intestinal Research Foundation | AbbVie Inc","highestDevelopmentStatusID":"11","companyTruncated":"St Vincent's Hospital Melbourne \/ Australasian Gastro Intestinal Research Foundation | AbbVie Inc"},{"orgOrder":0,"company":"Laboratorios Richmond S.A.C.I.F.","sponsor":"FP Clinical Pharma S.R.L. | Custom Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"ARGENTINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Undisclosed","graph2":"Phase I","graph3":"Laboratorios Richmond S.A.C.I.F.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratorios Richmond S.A.C.I.F. \/ FP Clinical Pharma S.R.L. | Custom Biologics","highestDevelopmentStatusID":"6","companyTruncated":"Laboratorios Richmond S.A.C.I.F. \/ FP Clinical Pharma S.R.L. | Custom Biologics"},{"orgOrder":0,"company":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","sponsor":"Prothya Biosolutions","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation \/ Prothya Biosolutions","highestDevelopmentStatusID":"11","companyTruncated":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation \/ Prothya Biosolutions"},{"orgOrder":0,"company":"Resilience Government Services","sponsor":"Pharm-Olam | CBRN Medical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Resilience Government Services","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Resilience Government Services \/ Pharm-Olam | CBRN Medical","highestDevelopmentStatusID":"10","companyTruncated":"Resilience Government Services \/ Pharm-Olam | CBRN Medical"},{"orgOrder":0,"company":"Jeffrey J Crowley MD","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Jeffrey J Crowley MD","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jeffrey J Crowley MD \/ AbbVie Inc","highestDevelopmentStatusID":"9","companyTruncated":"Jeffrey J Crowley MD \/ AbbVie Inc"},{"orgOrder":0,"company":"Mabscale","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase III","graph3":"Mabscale","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mabscale \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mabscale \/ Undisclosed"},{"orgOrder":0,"company":"Endeavor Health","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Urology","graph2":"Phase II","graph3":"Endeavor Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Endeavor Health \/ National Institute of Diabetes and Digestive and Kidney Diseases","highestDevelopmentStatusID":"8","companyTruncated":"Endeavor Health \/ National Institute of Diabetes and Digestive and Kidney Diseases"},{"orgOrder":0,"company":"Hamed Rezaei","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Hamed Rezaei","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hamed Rezaei \/ Abbott Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"Hamed Rezaei \/ Abbott Laboratories"},{"orgOrder":0,"company":"Jonathan Graf","sponsor":"American College of Rheumatology Research and Education Foundation | AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"Jonathan Graf","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jonathan Graf \/ American College of Rheumatology Research and Education Foundation | AbbVie Inc","highestDevelopmentStatusID":"11","companyTruncated":"Jonathan Graf \/ American College of Rheumatology Research and Education Foundation | AbbVie Inc"},{"orgOrder":0,"company":"Peter Higgins","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Peter Higgins","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peter Higgins \/ AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"Peter Higgins \/ AbbVie Inc"},{"orgOrder":0,"company":"waqqas.afif","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Undisclosed","graph3":"waqqas.afif","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"waqqas.afif \/ AbbVie Inc","highestDevelopmentStatusID":"1","companyTruncated":"waqqas.afif \/ AbbVie Inc"},{"orgOrder":0,"company":"Quallent Pharmaceuticals","sponsor":"Alvotech","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CAYMAN ISLANDS","productType":"Antibody, Unconjugated","year":"2024","type":"Agreement","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Quallent Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Quallent Pharmaceuticals \/ Alvotech","highestDevelopmentStatusID":"15","companyTruncated":"Quallent Pharmaceuticals \/ Alvotech"},{"orgOrder":0,"company":"Biocad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"RUSSIA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Biocad","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biocad \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biocad \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Adalimumab

    Menu

    Adalimumab

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AbbVie Inc

                            U.S.A
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Adalimumab

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Participants Requirin...

                            Details : Adalimumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Uveitis.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            June 10, 2022

                            Lead Product(s) : Adalimumab

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            AbbVie Inc

                            U.S.A
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Adalimumab

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Sponsor : Eisai

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Fully Human Anti-TNFα Monoclonal Antibody HUMIRA® Obtains Additional Approval for High-Dose Regimen of Ulcer...

                            Details : HUMIRA® is a fully human anti-TNF-α monoclonal antibody, got additional approval for a highdose regimen in adult patients with ulcerative colitis and for a new regimen in pediatric patients.

                            Product Name : Humira

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            September 27, 2021

                            Lead Product(s) : Adalimumab

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Sponsor : Eisai

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            AbbVie Inc

                            U.S.A
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Adalimumab

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Sponsor : Eisai

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AbbVie's Humira Gets Approval In Canada for Treatment of Pediatric Patients With Ulcerative Colitis

                            Details : HUMIRA (adalimumab) is the first and only subcutaneous biologic treatment option for pediatric patients from 5 years of age with moderately to severely active ulcerative colitis.

                            Product Name : Humira

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            April 24, 2021

                            Lead Product(s) : Adalimumab

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Sponsor : Eisai

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            AbbVie Inc

                            U.S.A
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Adalimumab

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Sponsor : Eisai

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            HUMIRA® (adalimumab) Receives FDA Approval to Treat Pediatric Patients Living with Moderately to Severely Act...

                            Details : Approval for adalimumab based on results from the pivotal Phase 3 ENVISION I study showing the higher dosage of HUMIRA induced clinical remission in 60 percent of patients at Week 8 and 45 percent of patients, who responded at Week 8, were in remission a...

                            Product Name : Humira

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            February 24, 2021

                            Lead Product(s) : Adalimumab

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Sponsor : Eisai

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            medac

                            Germany
                            PDA Universe
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Boothmedac CDMO: Tailored CDMO services for injectables in syringes, cartridges & vials – aseptic, reliable, flexible and a solution ahead.

                            Lead Product(s) : Adalimumab

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Sponsor : Fresenius Kabi AB Brunna

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Fresenius Kabi Enters Marketing Agreement For Biosimilar Product

                            Details : Medac’s sales representatives will begin offering the adalimumab biosimilar IDACIO® as an additional therapy option to the rheumatologists and dermatologists they work with.

                            Product Name : Idacio

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            May 28, 2020

                            Lead Product(s) : Adalimumab

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Sponsor : Fresenius Kabi AB Brunna

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            AbbVie Inc

                            U.S.A
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Adalimumab

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Particip...

                            Details : Adalimumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pyoderma Gangrenosum.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            October 17, 2017

                            Lead Product(s) : Adalimumab

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            AbbVie Inc

                            U.S.A
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Adalimumab

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa

                            Details : Adalimumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hidradenitis Suppurativa.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            September 19, 2016

                            Lead Product(s) : Adalimumab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            AbbVie Inc

                            U.S.A
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Adalimumab

                            Therapeutic Area : Immunology

                            Study Phase : Phase IV

                            Sponsor : IST GmbH | Hannover Medical School | Improvement by Movement

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study Treating Participants With Early Axial Spondyloarthritis (axSpA) Taking an Intense Treatment Approach ...

                            Details : Adalimumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Axial Spondyloarthritis.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            September 13, 2016

                            Lead Product(s) : Adalimumab

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase IV

                            Sponsor : IST GmbH | Hannover Medical School | Improvement by Movement

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            AbbVie Inc

                            U.S.A
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Adalimumab

                            Therapeutic Area : Dermatology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically

                            Details : Adalimumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hidradenitis Suppurativa.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            June 22, 2016

                            Lead Product(s) : Adalimumab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            AbbVie Inc

                            U.S.A
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Adalimumab

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Long-term Safety and Efficacy Study of Adalimumab in Pediatric Subjects With Ulcerative Colitis

                            Details : Adalimumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Colitis, Ulcerative.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            December 16, 2015

                            Lead Product(s) : Adalimumab

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth